GB2328155B - Methods of treating immunopathologies using polyunsaturated fattyacids - Google Patents

Methods of treating immunopathologies using polyunsaturated fattyacids

Info

Publication number
GB2328155B
GB2328155B GB9822203A GB9822203A GB2328155B GB 2328155 B GB2328155 B GB 2328155B GB 9822203 A GB9822203 A GB 9822203A GB 9822203 A GB9822203 A GB 9822203A GB 2328155 B GB2328155 B GB 2328155B
Authority
GB
United Kingdom
Prior art keywords
immunopathologies
fattyacids
polyunsaturated
treating
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9822203A
Other languages
English (en)
Other versions
GB2328155A (en
GB9822203D0 (en
Inventor
Antonio Ferrante
Alfred Poulos
Michael Joseph Pitt
Christopher John Easton
Merilyn Joy Sleigh
Deborah Ann Rathjen
Fred Widmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Women's and Children's Hospital
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Women's and Children's Hospital
Peptide Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN9250A external-priority patent/AUPN925096A0/en
Priority claimed from AUPN9538A external-priority patent/AUPN953896A0/en
Application filed by Women's and Children's Hospital, Peptide Technology Ltd filed Critical Women's and Children's Hospital
Publication of GB9822203D0 publication Critical patent/GB9822203D0/en
Publication of GB2328155A publication Critical patent/GB2328155A/en
Application granted granted Critical
Publication of GB2328155B publication Critical patent/GB2328155B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB9822203A 1996-04-12 1997-04-14 Methods of treating immunopathologies using polyunsaturated fattyacids Expired - Fee Related GB2328155B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN9250A AUPN925096A0 (en) 1996-04-12 1996-04-12 Methods of treatment
AUPN9538A AUPN953896A0 (en) 1996-04-26 1996-04-26 Treatment of t-cell mediated diseases
PCT/AU1997/000231 WO1997038688A1 (en) 1996-04-12 1997-04-14 Methods of treating immunopathologies using polyunsaturated fattyacids

Publications (3)

Publication Number Publication Date
GB9822203D0 GB9822203D0 (en) 1998-12-02
GB2328155A GB2328155A (en) 1999-02-17
GB2328155B true GB2328155B (en) 2000-08-02

Family

ID=25645159

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9822203A Expired - Fee Related GB2328155B (en) 1996-04-12 1997-04-14 Methods of treating immunopathologies using polyunsaturated fattyacids

Country Status (6)

Country Link
US (1) US6262119B1 (enExample)
EP (1) EP0904072A4 (enExample)
JP (1) JP2000508645A (enExample)
CA (1) CA2251780A1 (enExample)
GB (1) GB2328155B (enExample)
WO (1) WO1997038688A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1123314B1 (en) * 1998-10-20 2004-02-18 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of a cytokine-producing lactococcus strain to treat colitis
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
JP5048201B2 (ja) 2000-08-04 2012-10-17 ディーエムアイ バイオサイエンシズ インコーポレイテッド ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
DK1571970T3 (da) * 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
AU2003298291A1 (en) * 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
EP2324828A1 (en) * 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
DE10351111A1 (de) * 2003-11-03 2005-06-16 Langlotz, Rainer Arzneimittel und Verfahren zu ihrer Herstellung
JP2007522118A (ja) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
US7544714B2 (en) * 2004-07-16 2009-06-09 University Of Massachusetts Lipid-amino acid conjugates and methods of use
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US20060246115A1 (en) * 2005-03-04 2006-11-02 Ricardo Rueda Nutritional products for ameliorating symptoms of rheumatoid arthritis
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
BRPI0807857A2 (pt) 2007-01-25 2014-05-27 Actogenix Nv Tratamento de doença imune por meio de distribuição através da mucosa de antígenos.
WO2009006668A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent t cell proliferation
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
JP5856843B2 (ja) * 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
KR101783817B1 (ko) * 2009-05-08 2017-10-23 프로노바 바이오파마 너지 에이에스 심혈관 질병, 대사 질병, 및 염증성 질환 분야관련 질병의 치료를 위한 다중 불포화 지방산
GB0909643D0 (en) 2009-06-04 2009-07-22 Avexxin As Glomerulonephritis treatment
GB201014633D0 (en) 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
SG10201509127YA (en) 2010-11-05 2015-12-30 Pronova Biopharma Norge As Methods of treatment using lipid compounds
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
JP6248092B2 (ja) 2012-03-30 2017-12-13 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル化１−アミノシクロアルキルカルボン酸
WO2013149008A2 (en) * 2012-03-30 2013-10-03 Givaudan, S.A. Improvements in or relating to organic compounds
US10856563B2 (en) 2012-03-30 2020-12-08 Givaudan S.A. N-acyl-amino acid derivatives for improvement of the flavor profile of edible compositions
SG11201405413SA (en) 2012-03-30 2014-10-30 Givaudan Sa N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds
US10582715B2 (en) 2012-03-30 2020-03-10 Givaudan Sa Powder flavour composition
CN104219964B (zh) 2012-03-30 2016-09-21 奇华顿股份有限公司 作为食品加香化合物的n-酰基脯氨酸衍生物
JP6320367B2 (ja) 2012-03-30 2018-05-09 ジボダン エス エー 食品フレーバー付与化合物としてのｎ−アシル化メチオニン誘導体
BR122020006518B1 (pt) 2012-03-30 2022-02-22 Givaudan Sa Composição de sabor
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
US11351139B2 (en) 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
GB201317424D0 (en) 2013-10-02 2013-11-13 Givaudan Sa Improvements in or relating to organic compounds
EP3057448B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
EP3057446B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
CN105636934B (zh) 2013-10-02 2019-03-29 奇华顿股份有限公司 N-酰化的2-氨基异丁酸化合物和包含它们的香味组合物
WO2015050535A1 (en) 2013-10-02 2015-04-09 Givaudan S.A. Organic compounds
EP3057447B1 (en) 2013-10-02 2017-12-06 Givaudan S.A. Organic compounds having taste-modifying properties
WO2015048991A1 (en) 2013-10-02 2015-04-09 Givaudan Sa Organic compounds having taste-modifying properties
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
WO2017156164A1 (en) 2016-03-09 2017-09-14 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000326A1 (de) * 1991-06-25 1993-01-07 Basf Aktiengesellschaft Omega-3 mehrfach ungesättigte fettsäurederivate, ihre herstellung und verwendung
EP0582834A1 (en) * 1992-08-11 1994-02-16 Prospa B.V. Pharmaceutical compositions containing esters of omega-3 polyunsatured acids and their use in the topical treatment of morbid affections
AU3156595A (en) * 1994-08-11 1996-03-07 J.W. Broadbent Nominees Pty. Ltd. Anti-inflammatory preparation
AU3645195A (en) * 1994-10-13 1996-05-06 Children, Youth And Women's Health Service Incorporated Modified polyunsaturated fatty acids
AU3765895A (en) * 1994-10-26 1996-05-23 Children, Youth And Women's Health Service Incorporated Synthetic polyunsaturated fatty acid analogues
US5585400A (en) * 1996-02-27 1996-12-17 Wisconsin Alumni Research Foundation Methods of attenuating the allergic response in animals
US5616607A (en) * 1993-03-29 1997-04-01 Hsc Research And Development Limited Partnership Hepoxilin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK435087A (da) * 1986-09-10 1988-03-11 Hoffmann La Roche Isoprenderivater
JPS6372648A (ja) * 1986-09-16 1988-04-02 Sumitomo Pharmaceut Co Ltd 新規不飽和脂肪酸誘導体
JPH02225411A (ja) * 1989-02-28 1990-09-07 Nippon Oil & Fats Co Ltd 高度不飽和脂肪酸の溶血性低下方法
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
AUPM740594A0 (en) 1994-08-11 1994-09-01 J.W. Broadbent Nominees Pty. Ltd. Anti-inflammatory preparation
CN1088058C (zh) 1994-10-13 2002-07-24 肽技术有限公司 经修饰的多不饱和脂肪酸
AUPM906594A0 (en) 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000326A1 (de) * 1991-06-25 1993-01-07 Basf Aktiengesellschaft Omega-3 mehrfach ungesättigte fettsäurederivate, ihre herstellung und verwendung
EP0582834A1 (en) * 1992-08-11 1994-02-16 Prospa B.V. Pharmaceutical compositions containing esters of omega-3 polyunsatured acids and their use in the topical treatment of morbid affections
US5616607A (en) * 1993-03-29 1997-04-01 Hsc Research And Development Limited Partnership Hepoxilin analogs
AU3156595A (en) * 1994-08-11 1996-03-07 J.W. Broadbent Nominees Pty. Ltd. Anti-inflammatory preparation
AU3645195A (en) * 1994-10-13 1996-05-06 Children, Youth And Women's Health Service Incorporated Modified polyunsaturated fatty acids
AU3765895A (en) * 1994-10-26 1996-05-23 Children, Youth And Women's Health Service Incorporated Synthetic polyunsaturated fatty acid analogues
US5585400A (en) * 1996-02-27 1996-12-17 Wisconsin Alumni Research Foundation Methods of attenuating the allergic response in animals

Also Published As

Publication number Publication date
EP0904072A4 (en) 2003-07-30
EP0904072A1 (en) 1999-03-31
US6262119B1 (en) 2001-07-17
WO1997038688A1 (en) 1997-10-23
CA2251780A1 (en) 1997-10-23
JP2000508645A (ja) 2000-07-11
GB2328155A (en) 1999-02-17
GB9822203D0 (en) 1998-12-02

Similar Documents

Publication Publication Date Title
GB2328155A (en) Methods of treating immunopathologies using polyunsaturated fattyacids
GB9618420D0 (en) Fatty acid treatment
GB9617780D0 (en) Method of treatment
ZA971709B (en) Method of increasing testosterone
IL127421A0 (en) Process to prepare aryldiphosphoric esters
GB9605828D0 (en) Treatment method
GB2326952B (en) Method of providing microscopic features
GB9607609D0 (en) Cable treatment
GB9506837D0 (en) Triglycerides
GB9621373D0 (en) Fatty acid treatment
SG64990A1 (en) Method of treating polyolefin
PL313419A1 (en) Method of obtaining beta-naphtole
ZA973988B (en) Method of treatment
GB9618341D0 (en) Method of treatment
PL317788A1 (en) Method of obtaining 3-isocyanate-propylsilane
AU2498897A (en) Methods of treating immunopathologies using polyunsaturated fatty acids
HU9602005D0 (en) Cable and method for making said cable and use of said cable
KR100221732B1 (en) Reformative method of welding structure object
TW297472U (en) Structural of nut
PL315723A1 (en) Method of obtaining 3-hydroxy-3-phenyl-n-methyl propyloamine
TW310785U (en) Structural improvement of anti-loosing nut
TW296153U (en) Improved structure of separable clamp
GB9602404D0 (en) Methods of treatment
GB9600888D0 (en) Method of treatment
PL303296A1 (en) Method of examining power lines

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20110414